The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...